Boston — Frontier Medicines Corporation has expanded its leadership team with the appointments of Aaron Weitzman, M.D., as Chief Medical Officer; Mike Preigh, Ph.D., as Chief Technical Operations Officer; and Joelle Lufkin, M.P.H., as Senior Vice President, Clinical Development and Strategy.
The clinical-stage precision medicines company said the appointments come as it advances its oncology and immunology pipeline, including FMC-376, a dual KRAS G12C ON+OFF inhibitor. Frontier expects to present the first clinical data for FMC-376 during a rapid oral session at the ESMO Congress 2026.
The company is also advancing FMC-242, which is designed to disrupt the PI3Kα-RAS interaction and is approaching clinical development.
“Frontier is at an important stage of growth as we progress our programs and continue to realize the potential of our Frontier™ Platform. These appointments come at a crucial time, with the first clinical data for FMC-376, a dual KRAS G12C ON+OFF inhibitor, expected to be presented at the ESMO Congress 2026, and as FMC-242, a breaker of the PI3Kα-RAS interaction, approaches the clinic,” said Chris Varma, Ph.D., Co-Founder, Chairperson and Chief Executive Officer of Frontier Medicines.
“Aaron, Mike and Joelle each bring deep expertise in advancing innovative medicines from early development through regulatory approval and commercialization. Their collective experience across clinical development, medical strategy and technical operations strengthens our leadership team as we build a pipeline designed to address targets previously considered undruggable,” Varma added.
Weitzman is a board-certified medical oncologist with more than 25 years of pharmaceutical and biotechnology drug development experience. He has spent 15 years in senior clinical leadership roles at major pharmaceutical companies and more than a decade as an independent consultant and acting chief medical officer.
Most recently, Weitzman served as an independent consultant and clinical leader for several oncology programs, including Halda Therapeutics’ HLD-0915 and Arvinas’ ARV-110. He previously served as Chief Medical Officer of Tango Therapeutics and held clinical development roles supporting medicines including Cabometyx, Avastin and Tasigna.
He received his medical degree from the University of Western Ontario and completed his medical residency at Mount Sinai Medical Center and a clinical fellowship in medical oncology at Columbia-Presbyterian Medical Center in New York.
Preigh brings more than 30 years of experience in pharmaceutical product development and manufacturing. Most recently, he served as Chief Technical Officer of Day One Biopharmaceuticals, where he led chemistry, manufacturing and controls development, the New Drug Application filing and commercialization of Ojemda.
He previously worked as an independent consultant to biotechnology companies and, from 2005 to 2015, led the CMC team at Array BioPharma. The team developed, manufactured and filed Investigational New Drug applications for more than 20 new chemical entities, including Mektovi and Tukysa.
Preigh began his industry career at Pfizer, where he spent 12 years in manufacturing, quality and research and development. He holds a Ph.D. in chemistry from the University of Pittsburgh and a bachelor’s degree in chemistry from Illinois Wesleyan University.
Lufkin has nearly 30 years of global clinical development experience across oncology and other therapeutic areas. Before joining Frontier, she spent more than seven years as Principal of JLK Clinical Consulting, advising biotechnology companies and helping guide programs from candidate nomination through IND-enabling work and first-in-human studies.
She previously served as Senior Vice President of Development at Imara Therapeutics and spent nearly eight years at Flexion Therapeutics, ultimately serving as Vice President of Clinical Development. At Flexion, she helped advance Zilretta from IND through NDA approval and helped build the company’s clinical development organization.
Earlier in her career, Lufkin held positions at Synta Pharmaceuticals, Cubist Pharmaceuticals and Wyeth-Ayerst Research. She received her Master of Public Health from Boston University and her bachelor’s degree in biology from the University of Massachusetts Amherst.
